The Cancer Imaging Program of the National Cancer Institute (NCI) has submitted an investigational new drug application to the FDA for 18F-fluorothymidine (FLT). FLT is the result of a collaboration between the program and multimodality vendor GE Healthcare.
FLT is a PET agent that shows promise as a means of providing information about cellular proliferation, and could improve cancer therapy monitoring using PET imaging.
According to Waukesha, WI-based GE, the joint submission is under a clinical trials agreement, and involves the University of Washington, Johns Hopkins University, Virginia Commonwealth University Medical Center, and Massachusetts General Hospital.
The collaborative program will expand to investigate the clinical utility of FLT for treatment monitoring of lung, breast, and other cancers.
By AuntMinnie.com staff writers
December 1, 2004
Related Reading
GE's RSNA advances include 64-slice PET/CT, HDMR, November 28, 2004
GE, Maquet in MR-guided surgery collaboration, November 24, 2004
GE notches Hawkeye mark, November 24, 2004
Road to RSNA, GE Healthcare, November 10, 2004
Copyright © 2004 AuntMinnie.com
